Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, MD, MBA, as Chief Research & Development Officer

Source: Aerie Pharmaceuticals

Aerie Pharmaceuticals announced the appointment of David A. Hollander, MD, MBA, as Chief Research & Development Officer, an executive officer position reporting to Vicente Anido, Jr., PhD, Aerie’s Chairman and Chief Executive Officer. Dr. Hollander will commence his employment at Aerie on November 11, 2019 and will direct the company’s preclinical and clinical research and development groups, as well as medical and professional affairs. He was most recently Chief Medical Officer, Senior Vice President at Ora, Inc.

Dr. Hollander brings outstanding credentials and an impressive track record to Aerie. He holds a B.S. in Chemistry from Stanford University, an MD from the University of Pennsylvania School of Medicine and an MBA from the Wharton School. His post-doctoral training included an internship in internal medicine at Cedars-Sinai Medical Center, a residency in ophthalmology at UCSF, and a fellowship in cornea, external-ocular disease and refractive surgery at UCLA’s Jules Stein Eye Institute. He began his career on faculty at Jules Stein and served as Assistant Chief of Ophthalmology at the Greater Los Angeles VA Medical Center. He then spent a decade at Allergan where his leadership roles included Head of EyeCare for Global Medical Affairs, as well as VP and Therapeutic Area Head of Anterior Segment Clinical Development. During this time, he was able to continue to see patients and teach residents in the operating room and clinic as an ophthalmologist. He is an author on more than 75 peer-reviewed publications, has given more than 100 presentations nationally and internationally, and holds multiple patents.

Casey Kopczynski, Aerie’s Chief Scientific Officer, will retain his focus on innovation strategy, leading the newly formed Science and Technology Group including Aerie’s ophthalmic sustained-delivery implant platform, new product opportunities and acquisitions that expand Aerie’s pipeline, as well as representing Aerie at global medical and scientific meetings.

“We are very excited to have David Hollander join our executive team. His extensive clinical and R&D background as well as his global industry experience will be a significant asset to the company as we expand Rhopressa and Rocklatan globally as well as advance our ophthalmology pipeline,” Vicente Anido, Jr., PhD, Chairman and Chief Executive Officer at Aerie, said in a company news release.

“Aerie has already demonstrated its ability to grow into a major ophthalmic pharmaceutical company with the successful launches of Rhopressa and Rocklatan,” Dr. Hollander said. “I look forward to joining the team and contributing to its future growth.”

In connection with his acceptance as Chief Research & Development Officer of the Company, Dr. Hollander will receive awards totaling 110,000 stock options and 25,000 shares of restricted stock. The stock options will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting ratably on each of the subsequent 36 monthly anniversaries of the hire date; the restricted stock will vest over a period of 4 years in four equal annual installments on each anniversary of the hire date. This award was made outside of Aerie’s stockholder-approved equity incentive plan and was approved by the company’s independent directors as an inducement material to Dr. Hollander entering into employment with the company in reliance on NASDAQ Listing Rule 5635(c)(4), which requires this public announcement.

Related Content